drugset

drugset / Trial / NCT01665846

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01665846 ↗

Phase 1 Completed 4 enrolled University of Hawaii Oregon Health and Science University · collab

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to describe the radiologic findings on brain MRI after ferumoxytol administration in HIV-infected patients with cognitive impairment.

Timeline

Start: 2011-07
Primary completion: 2012-06
Completion: 2012-06

Publications

Background Neuwelt EA, Hamilton BE, Varallyay CG, Rooney WR, Edelman RD, Jacobs PM, Watnick SG. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int. 2009 Mar;75(5):465-74. doi: 10.1038/ki.2008.496. Epub 2008 Oct 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ferumoxytol	Diagnostic / imaging agent	4 mg/kg	Intravenous

Indications